Day 1

A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura.

A phase 1 open-label study to characterize the metabolism and excretion of a single dose of radiolabeled AL-335 administered in combination with Odalasvir and Simeprevir and administered alone in healthy male subjects

A double-blind, randomized, placebo-controlled, combined single and multiple ascending dose study to investigate the safety, tolerability and pharmacokinetic profile of AB928 in healthy volunteers.